Advertisement

Role of Ovarian Suppression in Early Premenopausal Breast Cancer

  • Prudence A. Francis
    Correspondence
    Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, 3000, Australia.
    Affiliations
    Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

    Sir Peter MacCallum Department of Oncology, Univeristy of Melbourne, Melbourne, Australia

    St Vincent's Hopsital Melbourne, Australia
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Beatson G.T.
        On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases.
        Lancet. 1896; ii: 104-107
        • De Courmelles F.V.
        La radiothérapie indirecte, ou dirigée par les corrélations organiques.
        Arch Elect Med. 1922; 32: 264
        • Early Breast Cancer Trialists' Collaborative Group
        Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.
        Lancet. 1992; 339: 1-15
        • Bonadonna G.
        • Brusamolino E.
        • Valgussa P.
        • et al.
        Combination chemotherapy as an adjuvant treatment in operable breast cancer.
        N Engl J Med. 1976; 294: 405-410
        • Early Breast Cancer Trialists' Collaborative Group
        Ovarian ablation in early breast cancer: overview of the randomized trials.
        Lancet. 1996; 348: 1189-1196
        • Griggs J.J.
        • Somerfield M.R.
        • Anderson H.
        • et al.
        American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer.
        J Clin Oncol. 2011; 29: 3939-3942
        • Pagani O.
        • O’ Neill A.
        • Castiglione M.
        • et al.
        Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group Trial VI.
        Eur J Cancer. 1998; 34: 632-640
        • Walshe J.M.
        • Denduluri N.
        • Swain S.M.
        Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.
        J Clin Oncol. 2006; 24: 5769-5779
        • Swain S.M.
        • Jeong J.-H.
        • Wolmark N.
        Amenorrhea from breast cancer therapy e not a matter of dose.
        N Engl J Med. 2010; 363: 2268-2270
        • International Breast Cancer Study Group
        Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
        J Clin Oncol. 2006; 24: 1332-1341
        • Aebi S.
        • Gelber S.
        • Castiglione-Gertsch M.
        • et al.
        Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?.
        Lancet. 2000; 355: 1869-1874
        • Goldhirsch A.
        • Gelber R.D.
        • Yothers G.
        • et al.
        Adjuvant therapy for very young women with breast cancer: need for tailored treatments.
        J Natl Cancer Inst Monogr. 2001; 30: 44-51
        • Ahn S.H.
        • Son B.H.
        • Kim S.W.
        • et al.
        Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea e a report from the Korean Breast Cancer Society.
        J Clin Oncol. 2007; 26: 2360-2368
        • Petrek J.A.
        • Naughton M.J.
        • Case L.D.
        • et al.
        Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study.
        J Clin Oncol. 2006; 24: 1045-1051
        • Goodwin P.J.
        • Ennis M.
        • Pritchard K.I.
        • et al.
        Risk of menopause during the first year after breast cancer diagnosis.
        J Clin Oncol. 1999; 17: 2365-2370
        • Smith I.E.
        • Dowsett M.
        • Yap Y.S.
        • et al.
        Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines.
        J Clin Oncol. 2006; 24: 2444-2447
        • Guerrero A.
        • Gavilá J.
        • Folkerd E.
        • et al.
        Incidence and predictors of ovarian function recovery in breast cancer patients with chemotherapy-induced amenorrhea who switched from tamoxifen to exemestane.
        Ann Oncol. 2013; 24: 674-679
        • Krekow L.K.
        • Hellerstedt B.A.
        • Collea R.P.
        • et al.
        Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole.
        J Clin Oncol. 2016; 34: 1594-1600
        • Regan M.M.
        • Pagani O.
        • Fleming G.F.
        • et al.
        Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials.
        Breast. 2013; 22: 1094-1100
        • Francis P.A.
        • Regan M.M.
        • Fleming G.F.
        • et al.
        Adjuvant ovarian suppression in premenopausal breast cancer.
        N Engl J Med. 2015; 372: 436-446
        • Burstein H.J.
        • Lacchetti C.
        • Anderson H.
        • et al.
        Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression.
        J Clin Oncol. 2016; 34: 1689-1701
        • Tevaarwerk A.J.
        • Wang M.
        • Zhao F.
        • et al.
        Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor–positive breast cancer (E-3193, INT-0142): A trial of the Eastern Cooperative Oncology Group.
        J Clin Oncol. 2014; 32: 3948-3958
        • Francis P.A.
        • Pagani O.
        • Fleming G.F.
        • et al.
        Tailoring adjuvant endocrine therapy for premenopausal breast cancer.
        N Engl J Med. 2018; 379: 122-137
        • Kim H.A.
        • Lee J.W.
        • Nam S.J.
        • et al.
        Adding ovarian suppression to tamoxifen for premenopausal breast cancer: A randomized phase III trial.
        J Clin Oncol. 2019; 37: 862-866
        • Ribi K.
        • Luo W.
        • Bernhard J.
        • et al.
        Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the Suppression of Ovarian Function Trial.
        J Clin Oncol. 2016; 34: 1601-1610
        • Regan M.M.
        • Francis P.A.
        • Pagani O.
        • et al.
        Absolute benefits of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials.
        J Clin Oncol. 2016; 34: 2221-2231
        • Pagani O.
        • Francis P.A.
        • Fleming G.F.
        • et al.
        Absolute improvements in freedom from distant recurrence by tailoring adjuvant endocrine therapies for premenopausal women with hormone receptor-positive HER2-negative breast cancer: results from TEXT and SOFT.
        J Clin Oncol. 2020; 38: 1293-1303
      1. Tailoring adjuvant endocrine therapy for premenopausal women: absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with HR+/HER2- breast cancer, as investigated in the TEXT and SOFT clinical trials, according to composite risk.
        (Available at:) (Accessed 19 June 2022)
        • Regan M.M.
        • Walley B.A.
        • Fleming G.F.
        • et al.
        Randomized comparison of adjuvant aromatase inhibitor exemestane plus ovarian function suppression (OFS) vs tamoxifen plus OFS in premenopausal women with hormone receptor-positive early breast cancer: update of the combined TEXT and SOFT trials.
        Cancer Res. 2022; 82 (GS2-05)
        • Early Breast Cancer Trialists’ Collaborative Group
        Aromatase inhibitors versus tamoxifen in premenopausal women with estrogen receptor-positive early breast cancer treated with ovarian suppression: patient level meta-analysis of 7,030 women in four randomized trials.
        Lancet Oncol. 2022; 23: 382-392
        • Gnant M.F.
        • Mlineritsch B.
        • Luschin-Ebengreuth G.
        • et al.
        Zolendronic acid prevents cancer treatment induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Study Group.
        J Clin Oncol. 2007; 25: 820-828
        • Ramchand S.K.
        • Seeman E.
        • Wang X.F.
        • et al.
        Premenopausal women with early breast cancer treated by oestradiol suppression have severely deteriorated bone microstructure: A cross sectional study.
        Bone. 2017; 103: 131-135
        • Gnant M.
        • Mlineritsch B.
        • Schippinger W.
        • et al.
        Endocrine therapy plus zolendronic acid in premenopausal breast cancer.
        N Engl J Med. 2009; 360: 679-691
        • Gnant M.
        • Mlineritsch B.
        • Stoeger H.
        • et al.
        Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
        Ann Oncol. 2015; 26: 313-320
        • Moore H.C.F.
        • Unger J.M.
        • Phillips K.A.
        • et al.
        Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
        N Engl J Med. 2015; 372: 923-932
        • Lambertini M.
        • Moore H.C.F.
        • Leonard R.C.F.
        • et al.
        Gonadotropin-Releasing Hormone Agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data.
        J Clin Oncol. 2018; 36: 198-1990
        • Regan M.M.
        • Pagani O.
        • Walley B.
        • et al.
        Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?.
        Ann Oncol. 2008; 19: 1231-1241
        • Sparano J.A.
        • Gray R.J.
        • Ravdin P.M.
        • et al.
        Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
        N Engl J Med. 2019; 380: 2395-2405
        • Kalinsky K.
        • Barlow W.E.
        • Gralow J.R.
        • et al.
        21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
        N Engl J Med. 2021; 385: 2336-2347
        • Piccart M.J.
        • van’t Veer L.J.
        • Pancet C.
        • et al.
        70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
        Lancet Oncol. 2021; 22: 476-488
        • Thurlimann B.
        • Price K.N.
        • Gelber R.D.
        • et al.
        Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
        Breast Cancer Res Treat. 2009; 113: 137-144